Highlights

  • Pacific Edge successfully completed a NZ$36.1 million Capital raising, exceeding initial targets.
  • The retail offer attracted strong investor Demand and was significantly oversubscribed.
  • Most participating shareholders received allocations sufficient to maintain their ownership positions.

Overview

Cancer diagnostics company Pacific Edge has successfully completed a NZ$36.1 million capital raising after receiving strong support from both institutional and retail investors. The fundraising included a NZ$25.4 million Placement and a retail offer that ultimately raised NZ$10.7 million after the company accepted additional oversubscriptions. Demand from eligible shareholders far exceeded expectations, with applications totaling NZ$46 million. The proceeds are expected to strengthen Pacific Edge's financial position and support the continued expansion of its Cxbladder diagnostic platform across key markets, including the United States and Asia-Pacific region.

Why Was Pacific Edge's Retail Offer So Popular Among Investors?

The retail offer generated substantial interest, attracting applications worth NZ$46 million despite an initial target of NZ$6 million. In response to the overwhelming demand, Pacific Edge increased the size of the offer and accepted NZ$4.7 million in oversubscriptions. The allocation process was designed to ensure that most shareholders could maintain their proportional ownership in the company. The strong participation highlights investor confidence in Pacific Edge's Long-term Growth strategy, particularly as the company advances commercialization efforts and expands the adoption of its Cxbladder cancer diagnostic tests.

How Will the NZ$36.1 Million Capital Raise Support Pacific Edge's Future Growth?

The additional capital provides Pacific Edge with greater financial flexibility to pursue strategic growth initiatives and strengthen its market position. Company Leadership believes the fundraising reflects confidence in the clinical evidence supporting Cxbladder, growing engagement from healthcare payers, and emerging opportunities across international markets. The company also highlighted positive developments in reimbursement discussions and regulatory milestones. With more than 93% of the funds coming from existing shareholders, Pacific Edge views the successful capital raise as a strong endorsement of its long-term vision and growth potential.